Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 6, 2012, Pages 982-992

  Wynes, Murry W ^a   Konopa, Krzysztof ^b   Singh, Shalini ^c   Reyna Asuncion, Bernadette ^a   Ranger Moore, James ^c   Sternau, Adam ^b   Christoph, Daniel C ^a   Dziadziuszko, Rafal ^b   Jassem, Jacek ^b   Hirsch, Fred R ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Biomarker; Gene copy number; Immunohistochemistry; In situ hybridization; Lung cancer; Pemetrexed; Prognosis; Protein expression; Thymidylate synthase

Indexed keywords

THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; GENE DOSAGE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SILVER IN SITU HYBRIDIZATION; SQUAMOUS CELL CARCINOMA;

EID: 84861337347     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824fe95a     Document Type: Article

References (33)

1. NSCLC Meta-Analysis Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-4625.
2. Grossi F, Aita M, Defferrari C, et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009;14:497-510.
3. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007;26:153-181. (Pubitemid 46452189)
4. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123. (Pubitemid 27138611)
5. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 2008;26:3543-3551.
6. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
7. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596. (Pubitemid 44546920)
8. Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010;101:161-166.
9. Bepler G, Sommers KE, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008;3:1112-1118.
10. Ooyama A, Okayama Y, Takechi T, Sugimoto Y, Oka T, Fukushima M. Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs. Cancer Sci 2007;98:577-583. (Pubitemid 46562750)
11. Gosens MJ, Moerland E, Lemmens VP, Rutten HT, Tan-Go I, van den Brule AJ. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 2008;123:1941-1949.
12. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010;28:2174-2180.
13. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010;34:767-776.
14. Koh YW, Lee HJ, Lee JW, Kang J, Gong G. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol 2011;24:794-800.
15. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I non-small cell lung cancer. Cancer 2008;112:2765-2773. (Pubitemid 351969222)
16. Nakagawa T, Otake Y, Yanagihara K, et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004;43:145-149. (Pubitemid 38114742)
17. Tanaka F, Wada H, Fukui Y, et al. Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol. 2011.
18. Takezawa K, Okamoto I, Tsukioka S, et al. Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br J Cancer 2010;103:354-361.
19. Hashimoto H, Ozeki Y, Sato M, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006;106:1595-1601.
20. Nakagawa T, Tanaka F, Otake Y, et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002;35:165-170. (Pubitemid 34136094)
21. Shimokawa H, Uramoto H, Onitsuka T, et al. TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer 2011;72:360-364.
22. Shintani Y, Ohta M, Hirabayashi H, et al. New prognostic indicator for non-small cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003;104:790-795. (Pubitemid 36418519)
23. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18:752-760. (Pubitemid 46523281)
24. Badzio A, Wynes MW, Dziadziuszko R, et al. Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol 2010;5:1905-1911.
25. Mascaux C, Wynes MW, Kato Y, et al. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor-a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res 2011;17:7796-7807.
26. Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010;5:1551-1558.
27. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807. (Pubitemid 46606235)
28. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005;97:643-655. (Pubitemid 40812628)
29. Merrick DT, Kittelson J, Winterhalder R, et al. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res 2006;12(7 Pt 1):2281-2288.
30. Dziadziuszko R, Wynes MW, Singh S, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012;7:340-347.
31. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
32. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol Pharmacol 2005;68: 110-118. (Pubitemid 41002949)
33. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25:417-423. (Pubitemid 47222911)